CD274 and esophageal squamous cell carcinoma: Compared with chemotherapy, nivolumab plus chemotherapy or ipilimumab as first-line therapy for PD-L1-positive advanced ESCC patients generated an incremental cost of $ 88,366.61 and $ 89,257.72 with additional 0.41 QALYs and 0.48 QALYs, respectively, resulting in an ICER of $216,628.00/QALY and $185,483.94/QALY.